Planning for a global market withdrawal of the multiple sclerosis (MS) drug Zinbryta (daclizumab) is underway after reports of seven cases of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, triggered "an urgent review" by the EMA of the medicine.